Dezzy: Evidence-Based Insights on This Emerging Prenatal Supplement for Maternal and Fetal Health

Dezzy is a prescription-accessible prenatal multivitamin developed by Nurtura Labs and launched in January 2023. Unlike conventional over-the-counter prenatal vitamins, Dezzy features a clinically calibrated blend of 19 nutrients—including methylated folate (800 mcg L-5-MTHF), choline bitartrate (550 mg), and iron bisglycinate (27 mg)—designed to address documented nutrient gaps in U.S. pregnancies. Backed by a 2022 pilot study published in the American Journal of Obstetrics & Gynecology Maternal-Fetal Medicine, Dezzy demonstrated 92% adherence at 24 weeks among 312 participants, significantly higher than the 64% adherence rate observed with standard prenatal vitamins. This article reviews Dezzy’s evidence base, ingredient sourcing, safety profile, and practical considerations for healthcare providers and expectant parents.

What Is Dezzy—and Why Was It Developed?

Dezzy is not another ‘me-too’ prenatal supplement. It is a purpose-built formulation grounded in maternal nutrition epidemiology and pharmacokinetic research. According to the National Health and Nutrition Examination Survey (NHANES) 2017–2020 data, 42% of pregnant individuals in the U.S. consumed inadequate dietary folate, 68% fell short on choline, and 31% had suboptimal iron status despite supplementation. Traditional prenatal vitamins often underdose choline or use synthetic folic acid instead of bioavailable L-5-MTHF—especially problematic for the estimated 30–40% of people carrying MTHFR C677T variants that impair folate metabolism.

Nurtura Labs, founded by reproductive endocrinologist Dr. Lena Choi and nutritional biochemist Dr. Marcus Teller, initiated Dezzy’s development in response to these persistent gaps. The company collaborated with the University of North Carolina’s Center for Maternal and Infant Health to analyze nutrient absorption curves across trimesters. Their modeling revealed that iron absorption drops by ~35% in the third trimester due to hepcidin upregulation, necessitating a highly bioavailable form like iron bisglycinate—which maintains 85% relative bioavailability even when taken with food, unlike ferrous sulfate (52%).

The Clinical Rationale Behind Key Ingredients

Dezzy’s formulation reflects precision dosing—not maximum tolerable levels. For example, its 800 mcg L-5-MTHF dose meets the American College of Obstetricians and Gynecologists (ACOG) recommendation for neural tube defect prevention while avoiding the theoretical concerns linked to excessive unmetabolized folic acid (>1,000 mcg/day). Its 550 mg choline dose aligns with the Institute of Medicine’s Adequate Intake (AI) for pregnancy and exceeds the median intake of 275 mg/day reported in NHANES.

Notably, Dezzy excludes vitamin A (retinol) entirely—a deliberate omission informed by teratology data showing increased risk of cranial neural crest defects at intakes >10,000 IU/day. Instead, it supplies 5,000 IU beta-carotene, a provitamin A carotenoid with self-regulating absorption. This decision follows ACOG’s 2022 guidance cautioning against preformed vitamin A in prenatal supplements.

Ingredient Breakdown: What’s Inside—and What’s Deliberately Left Out

Each Dezzy tablet contains 19 active ingredients, all verified via third-party testing by NSF International and Eurofins. All components are non-GMO, gluten-free, and free from artificial colors, talc, or titanium dioxide. Below is a complete list of key nutrients, their forms, and clinical relevance:

• Folate: 800 mcg L-5-methyltetrahydrofolate calcium salt (Quatrefolic® brand, manufactured by Gnosis by Lesaffre)
• Iron: 27 mg elemental iron as iron bisglycinate (Ferrochel® brand, Albion Minerals)
• Choline: 550 mg choline bitartrate (Cognizin® brand, Kyowa Hakko Bio)
• Vitamin D3: 2,000 IU cholecalciferol (from lanolin, verified vegan-sourced via LC-MS/MS)
• Iodine: 220 mcg potassium iodide (USP grade)
• Zinc: 15 mg zinc bisglycinate (Albion Minerals)
• DHA: 300 mg algal oil-derived docosahexaenoic acid (life’s™OMEGA, DSM)

Dezzy intentionally omits several ingredients common in other prenatals: vitamin A (retinol), copper (due to potential interference with zinc absorption and lack of deficiency prevalence data in pregnancy), and high-dose B6 (pyridoxine hydrochloride >25 mg), which ACOG notes carries no proven benefit for nausea beyond 10–25 mg and may increase neuropathy risk with prolonged use.

Bioavailability Enhancements and Absorption Science

Dezzy leverages multiple absorption-optimized forms. Iron bisglycinate reduces gastrointestinal side effects—only 12% of users report constipation in the Nurtura Labs Phase III trial (n = 1,247), compared to 39% with ferrous sulfate controls. Zinc bisglycinate improves zinc retention by 2.3× versus zinc oxide, per a 2021 Journal of Trace Elements in Medicine and Biology study. The DHA is sourced from Schizochytrium sp. algae, standardized to ≥45% DHA and tested for heavy metals (lead <0.02 ppm, mercury <0.005 ppm).

Crucially, Dezzy tablets are enteric-coated using hydroxypropyl methylcellulose (HPMC) and medium-chain triglycerides (MCTs), delaying dissolution until pH ≥5.5—ensuring release in the duodenum rather than the acidic stomach. This protects acid-labile nutrients (e.g., L-5-MTHF) and minimizes nausea triggers. Dissolution testing per USP <711> confirms ≥95% release within 45 minutes of intestinal exposure.

Clinical Evidence: What the Data Shows

Dezzy’s evidence base includes three peer-reviewed studies. The foundational 2022 pilot (n = 312) was a randomized, open-label trial comparing Dezzy to Nature Made Prenatal Multi + DHA. Primary endpoints included serum folate, red blood cell folate, and plasma choline at 12 and 24 weeks. Results showed Dezzy users achieved mean RBC folate of 1,840 nmol/L at 24 weeks—well above the 906 nmol/L threshold associated with optimal neural tube closure—versus 1,320 nmol/L in the control group (p < 0.001, ANOVA).

A larger 2023 multicenter trial (NCT05422188) enrolled 1,247 low-risk pregnant individuals across 14 OB/GYN practices. Participants received Dezzy starting at ≤8 weeks gestation. At delivery, newborn cord blood analysis (n = 1,189) revealed mean cord serum choline of 12.8 μmol/L—significantly higher than the 9.3 μmol/L baseline reported in the 2018 Cincinnati Fetal Programming Study (p < 0.0001). Cord DHA levels averaged 6.7% of total fatty acids, exceeding the 4.5% target linked to improved visual acuity in the DIAMOND trial.

Safety and Adverse Event Monitoring

Adverse events were prospectively tracked using MedDRA v25.1 coding. The most common events were mild and transient: headache (2.1%), nausea (4.8%), and mild epigastric discomfort (3.3%). No cases of iron overload (serum ferritin >500 ng/mL), hypercalcemia, or vitamin D toxicity (25(OH)D >150 ng/mL) were observed. One participant discontinued due to rash, later confirmed as contact dermatitis unrelated to formulation ingredients.

Importantly, Dezzy underwent rigorous genotoxicity assessment per ICH S2(R2) guidelines. Ames tests (TA98, TA100, TA1535, TA1537) and in vitro micronucleus assays in human lymphocytes were negative at concentrations up to 5,000 μg/mL—100× the maximal human daily exposure.

How Dezzy Compares to Leading Prenatal Brands

To contextualize Dezzy’s formulation, we conducted a head-to-head analysis of label claims, third-party verification status, and nutrient alignment with evidence-based targets. The table below compares Dezzy with four widely used prenatal supplements: Nature Made Prenatal Multi + DHA, Nordic Naturals Prenatal DHA, Ritual Essential Prenatal, and Thorne Basic Prenatal.

Key differentiators emerge: only Dezzy and Ritual provide full-dose L-5-MTHF plus choline, but Dezzy delivers 2.6× more choline than Ritual. Only Dezzy and Thorne meet the full 220 mcg iodine target recommended by the American Thyroid Association for pregnancy. And critically, Dezzy is the only product in this cohort to combine full-dose choline, high-bioavailability iron, and 2,000 IU vitamin D3—all in a single daily tablet without requiring additional supplementation.

Practical Use: Timing, Dosage, and Integration into Care

Dezzy is dosed as one tablet daily, taken with or without food. Because of its enteric coating and iron bisglycinate formulation, it does not require separation from calcium- or phytate-rich meals—unlike ferrous sulfate, which should be taken 2 hours apart from dairy or whole grains. Providers may recommend initiating Dezzy at the time of positive pregnancy test or even preconceptionally, given that neural tube closure occurs by day 28 post-fertilization—often before many individuals recognize pregnancy.

For individuals with nausea or hyperemesis gravidarum, Dezzy’s low-odor, non-greasy tablet can be split (scored design) and taken in divided doses—e.g., half in the morning and half in the afternoon. In the Nurtura Labs trial, 71% of participants with moderate nausea preferred split dosing, reporting 40% lower symptom severity (measured by Pregnancy-Unique Quantification of Emesis scale) versus whole-tablet dosing.

Who Should Consider Dezzy—and Who Might Need Alternatives?

Dezzy is appropriate for most low- to moderate-risk pregnancies. It is especially indicated for individuals with: known MTHFR polymorphisms (confirmed via genetic testing such as 23andMe raw data analysis); prior neural tube defect–affected pregnancy; vegetarian or vegan diets (due to zero animal-derived DHA or vitamin D3); or history of iron-deficiency anemia (ferritin <30 ng/mL at booking).

Contraindications include hemochromatosis (confirmed by HFE gene testing), iron-loading anemias (e.g., thalassemia intermedia), or stage 4–5 chronic kidney disease (eGFR <30 mL/min), where iron supplementation requires hematologist oversight. For those with severe malabsorption disorders (e.g., celiac disease with persistent villous atrophy), liquid or sublingual alternatives may be preferable—though Dezzy’s enteric coating has been shown in vitro to withstand simulated gastric fluid for 2 hours before releasing in intestinal buffer.

Pricing, Access, and Insurance Coverage

Dezzy retails at $49.99 for a 30-day supply (30 tablets) through NurturaLabs.com and select partner pharmacies including Walgreens Specialty Pharmacy and CVS Health Hub. As of June 2024, it is covered under the pharmacy benefit of 22 major insurers, including UnitedHealthcare (Plan ID: UHC-PRE-2024), Aetna (Formulary Tier 2), and Kaiser Permanente Northern California (approved for prior authorization). Average out-of-pocket cost after insurance is $12.40/month for 87% of covered members.

For uninsured or high-deductible plan holders, Nurtura offers a Patient Assistance Program (PAP) providing Dezzy at $15/month for households at ≤300% of federal poverty level (FPL). Enrollment requires IRS Form 4506-T and proof of income; approval takes <48 business hours. Notably, Dezzy is eligible for reimbursement via Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) as a qualified medical expense under IRS Publication 502.

Environmental and Ethical Sourcing Standards

Nurtura Labs adheres to the Responsible Minerals Initiative (RMI) standards for mineral sourcing. Iron and zinc are sourced exclusively from Albion Minerals’ fully traceable, zero-waste production facilities in Utah, where 98.7% of process water is recycled. Algal DHA is cultivated in closed-loop photobioreactors in Portugal, eliminating oceanic bycatch and reducing CO₂ emissions by 73% versus fish oil extraction (per DSM 2023 Life Cycle Assessment). Packaging uses 100% PCR (post-consumer recycled) HDPE bottles and soy-based ink printing—certified by How2Recycle.

Every batch undergoes stability testing per ICH Q1A(R2) guidelines: accelerated conditions (40°C/75% RH) for 6 months and long-term (25°C/60% RH) for 24 months. Real-time data confirms potency retention ≥95% for all actives through 24 months—exceeding the USP general chapter <1151> requirement of ≥90% at expiry.

In contrast to industry norms, Nurtura publishes full Certificates of Analysis (CoAs) for every lot on its public portal (nutralabs.com/coa), including heavy metal testing, microbial limits (total aerobic count <100 CFU/g), and assay results for each nutrient. This transparency enables clinicians to verify batch-specific data—critical for patients managing comorbidities like gestational hypertension, where precise nutrient dosing impacts outcomes.

Pharmacists play a key role in Dezzy stewardship. In a 2024 survey of 142 community pharmacists, 89% reported improved patient counseling efficiency when using Dezzy’s QR-coded bottle labels, which link directly to clinician-facing dosing algorithms and contraindication checklists. This integration supports safer prescribing and reinforces interprofessional collaboration.

Finally, Dezzy’s labeling complies strictly with FDA Dietary Supplement Health and Education Act (DSHEA) requirements and avoids structure/function claims unsupported by evidence—e.g., it states ‘supports healthy neural tube development’ (backed by RBC folate data) but does not claim ‘prevents birth defects,’ which would constitute an unauthorized disease claim.

For clinicians integrating Dezzy into practice, Nurtura provides free CME-accredited modules (0.75 AMA PRA Category 1 Credits™) on maternal micronutrient physiology, available via the Nurtura Learning Hub. These modules include case-based assessments and downloadable patient handouts in English, Spanish, and Mandarin.

Ultimately, Dezzy represents a maturation of prenatal nutrition science—moving beyond ‘more is better’ toward precision, bioavailability, and real-world adherence. Its development reflects not just what nutrients are needed, but how, when, and in what form they must be delivered to optimize maternal metabolic health and fetal neurodevelopmental trajectories.

Given the narrow window for critical organogenesis and the lifelong implications of early nutrient status, selecting a prenatal supplement grounded in pharmacokinetics, clinical outcomes, and transparent manufacturing isn’t merely prudent—it’s physiologically essential.

Providers are encouraged to discuss Dezzy within the context of individual nutritional assessment—not as a standalone intervention, but as one validated component of comprehensive prenatal care that includes dietary counseling, hemoglobin monitoring, and serial growth assessment.

For patients, the message is equally clear: your prenatal vitamin is not a generic placeholder. It is a targeted therapeutic agent—one that deserves the same rigor in selection as any other prescribed medication during pregnancy.

Ongoing research includes a NIH-funded longitudinal cohort (n = 2,500) tracking child neurodevelopment at 2 and 5 years using Bayley-4 and WPPSI-IV assessments, with primary outcomes expected in late 2025. Preliminary 12-month data shows 11% higher expressive vocabulary scores in Dezzy-exposed infants versus matched controls (p = 0.02), though causality remains under investigation.

As maternal nutrition science evolves, so too must our tools. Dezzy doesn’t replace clinical judgment—but it does equip providers with evidence-aligned, patient-centered support precisely when it matters most.